Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.
DROPLeT
1 other identifier
observational
130
1 country
1
Brief Summary
The study aims is to find out if people with type 1 diabetes diagnosed in later life (after age 30) have the same rapid loss of insulin secretion (measured using C-peptide) that occurs in younger adults with type 1 diabetes. The investigators will recruit 135 participants aged over 30 years with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. The investigators will also recruit a comparison group of 61 participants aged 18-30 with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. C-peptide will be measured during mixed meal tolerance tests (MMTT) performed at baseline, 6 months and a year. This study also aims to test a new more practical way of monitoring insulin secretion at home using a finger prick 'blood spot' rather than time consuming tests in a hospital. Finger-prick C-peptide samples will be collected after the MMTT and by the participants at home throughout the year.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2019
CompletedFirst Submitted
Initial submission to the registry
December 15, 2020
CompletedFirst Posted
Study publicly available on registry
December 23, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedJune 4, 2024
June 1, 2024
3.8 years
December 15, 2020
June 3, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
C-peptide value at a year
12 month (Mixed Meal Tolerance Test) MMTT area under the curve (AUC) C-peptide.
12 months
Change in C-peptide over a year
Rate of change of MMTT AUC C-peptide over 12 months assessed at regular study visits
12 months
Secondary Outcomes (3)
C-peptide value at 12 months
12 months
Glucose variability & hypoglycemia
12 months
Change in dried blood spot C-peptide
12 months
Study Arms (2)
Late Onset
Participants diagnosed with Type 1 diabetes at over 30 years of age.
18 to 30
Participants diagnosed with Type 1 diabetes between 18 and 30 years of age
Eligibility Criteria
Recent clinical diagnosis of type 1 diabetes
You may qualify if:
- Adults with a clinical diagnosis of Type 1 diabetes within the previous 100 days.
- Aged \>30 at the time of Type 1 diabetes diagnosis OR (additional early onset Type 1 diabetes cohort) aged ≥18 and ≤30 at the time of Type 1 diabetes diagnosis.
- Insulin treated at the time of recruitment
- Able and willing to provide informed consent.
You may not qualify if:
- Pregnancy
- Known monogenic diabetes
- Known secondary diabetes (diabetes considered likely due to medication, cystic fibrosis, pancreatitis, pancreatic cancer, pancreatic surgery, hemochromatosis or Cushing's syndrome).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Devon & Exeter NHS Foundation Trust
Exeter, Devon, EX2 5DW, United Kingdom
Related Publications (1)
Thomas NJ, Lynam AL, Hill AV, Weedon MN, Shields BM, Oram RA, McDonald TJ, Hattersley AT, Jones AG. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019 Jul;62(7):1167-1172. doi: 10.1007/s00125-019-4863-8. Epub 2019 Apr 10.
PMID: 30969375BACKGROUND
Biospecimen
Serum, Plasma, DNA,
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Angus Jones, MBBS MRCP
NIHR Exeter Clinical Research Facility
- PRINCIPAL INVESTIGATOR
Nicholas Thomas, MRCP
NIHR Exeter Clinical Research Facility
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 15, 2020
First Posted
December 23, 2020
Study Start
November 1, 2019
Primary Completion
September 1, 2023
Study Completion
December 31, 2023
Last Updated
June 4, 2024
Record last verified: 2024-06